
In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.
In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.
The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.
Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.
The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.
Published: August 29th 2025 | Updated: September 2nd 2025
Published: July 28th 2025 | Updated: July 30th 2025
Published: May 14th 2025 | Updated: May 16th 2025
Published: May 12th 2025 | Updated: May 13th 2025
Published: March 27th 2025 | Updated: March 28th 2025
Published: March 4th 2025 | Updated: March 19th 2025